AMGEN INC

AMGN
Biological products no disgnostic substances
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance SheetCash Flow
Period
Annual Quarterly
Order

40 more quarters with Pro

AMGEN INC back to 2009, every line as filed.

Create a free account
USD ($)
$ in Millions 		Jun 30, 2026Mar 31, 2026Sep 30, 2025Jun 30, 2025Mar 31, 2025Sep 30, 2024Jun 30, 2024Mar 31, 2024Sep 30, 2023Jun 30, 2023Mar 31, 2023Sep 30, 2022Jun 30, 2022Mar 31, 2022Sep 30, 2021Jun 30, 2021Mar 31, 2021Sep 30, 2020Jun 30, 2020Mar 31, 2020Sep 30, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jun 30, 2018Mar 31, 2018Sep 30, 2017Jun 30, 2017Mar 31, 2017Sep 30, 2016Jun 30, 2016Mar 31, 2016Sep 30, 2015Jun 30, 2015Mar 31, 2015Sep 30, 2014Jun 30, 2014Mar 31, 2014Sep 30, 2013Jun 30, 2013Mar 31, 2013Sep 30, 2012Jun 30, 2012Mar 31, 2012Sep 30, 2011Jun 30, 2011Mar 31, 2011Sep 30, 2010Jun 30, 2010Mar 31, 2010Sep 30, 2009Jun 30, 2009
Cash flows from operating activities:
                                                    
Net income
$ 2,375
$ 1,819
$ 3,216
$ 1,432
$ 1,730
$ 2,830
$ 746
$ (113)
$ 1,730
$ 1,379
$ 2,841
$ 2,143
Noncash adjustments to reconcile net income to net cash provided by operating activities:
                                                    
Depreciation, amortization and other
1,112
1,116
1,307
1,341
1,387
1,396
1,400
1,399
895
896
900
837
Impairment of intangible assets
-
0
400
-
800
-
-
-
-
-
-
-
Stock-based compensation expense
165
75
127
157
85
136
157
103
-
-
-
-
Deferred income taxes
(291)
(176)
(30)
(422)
(250)
(110)
(383)
(401)
(447)
(154)
(49)
(333)
Acquired in-process research and development
-
-
-
-
-
-
-
-
-
-
-
0
Adjustments for equity method investments
-
-
-
-
-
28
(12)
(27)
(14)
28
(31)
(216)
Loss (gain) on equity securities
158
143
(1,971)
554
(1,295)
(1,633)
401
515
(135)
661
(1,830)
-
Loss on divestiture
-
-
-
-
-
-
-
-
-
-
-
5
Other items, net
75
(67)
(28)
(23)
(50)
68
28
(95)
678
184
(13)
(200)
Changes in operating assets and liabilities, net of acquisitions:
                                                    
Trade receivables, net
(1,093)
413
222
(515)
(1,308)
(342)
(176)
486
(342)
(96)
(144)
(62)
Inventories
(31)
18
240
239
288
681
722
806
(54)
30
(58)
(241)
Other assets
(330)
8
(283)
(206)
(201)
(299)
(250)
(89)
(263)
70
(139)
(32)
Accounts payable
(70)
571
(174)
589
497
(122)
643
23
156
(118)
(253)
(44)
Accrued income taxes, net
(131)
71
610
(2,417)
104
247
(1,534)
223
527
28
443
193
Long-term tax liabilities
77
71
74
92
70
76
78
(715)
97
89
107
77
Accrued liabilities
901
(959)
(200)
824
(874)
(275)
693
(1,054)
-
-
-
-
Accrued sales incentives and allowance
1,117
(839)
1,184
627
486
929
(77)
(316)
-
-
-
-
Other liabilities
(32)
(75)
(10)
8
(78)
(39)
23
(56)
(68)
1,112
(710)
419
Other accrued liabilities
-
-
-
-
-
-
-
-
-
-
-
-
Deferred revenue
-
-
-
-
-
-
-
-
-
-
-
-
Net cash provided by operating activities
4,002
2,189
4,684
2,280
1,391
3,571
2,459
689
2,760
4,109
1,064
2,978
Cash flows from investing activities:
                                                    
Purchases of intangible assets
-
-
-
-
-
-
-
-
-
-
-
-
Proceeds from the sale of property, plant and equipment
-
-
-
-
-
-
-
-
-
-
-
-
Purchases of marketable securities
-
-
-
-
-
-
-
-
(1)
-
-
(387)
Proceeds from sales of marketable securities
-
-
-
-
-
-
-
0
-
1
1,124
-
Proceeds from maturities of marketable securities
-
-
-
-
-
-
-
0
-
-
550
400
Payments to Acquire Businesses, Net of Cash Acquired
-
-
-
-
-
-
-
-
-
-
-
-
Purchases of property, plant and equipment
(513)
(712)
(436)
(369)
(411)
(257)
(238)
(230)
(248)
(271)
(344)
(160)
Purchases of equity method investments
-
-
-
-
-
-
-
-
-
-
-
-
Change in restricted investments
-
-
-
-
-
-
-
-
-
-
-
-
Restriction of investments
-
-
-
-
-
-
-
-
-
-
-
-
Other
(56)
(4)
22
(20)
(36)
47
21
13
(13)
59
28
(120)
Net cash used in investing activities
(569)
(716)
(414)
(389)
(447)
(210)
(217)
(217)
(262)
(211)
1,358
(267)
Cash flows from financing activities:
                                                    
Net proceeds from issuance of debt
-
3,964
-
-
-
-
-
0
1
(18)
23,798
2,984
Extinguishment of debt
-
(233)
(81)
(301)
(301)
(249)
-
(410)
(130)
-
(420)
(297)
Repayment of debt
-
(833)
(15)
(10)
(2,500)
(2,200)
(1,400)
0
(750)
-
(704)
-
Net change in commercial paper
-
-
-
-
-
-
-
-
-
-
-
-
Repurchases of common stock
-
-
-
-
-
-
-
-
-
-
0
-
Dividends paid
(1,362)
(1,358)
(1,282)
(1,280)
(1,279)
(1,210)
(1,209)
(1,208)
(1,140)
(1,139)
(1,137)
(1,038)
Withholding taxes arising from shares withheld for share-based payments
-
-
-
-
-
-
-
-
-
-
-
-
Settlement of contingent consideration obligation
-
-
-
-
-
-
-
-
-
-
-
-
Net proceeds from issuance of common stock in connection with the Company’s equity award programs
-
-
-
-
-
-
-
-
-
-
-
-
Net proceeds from issuance of commercial paper
-
-
-
-
-
-
-
-
-
-
-
-
Other
(120)
(104)
10
(92)
(27)
8
(40)
(90)
14
(53)
(28)
(61)
Net cash used in financing activities
(1,482)
1,436
(2,853)
(2,673)
(4,107)
(3,651)
(2,649)
(1,708)
(2,005)
(1,210)
21,509
1,588
Increase in cash and cash equivalents
-
-
-
-
-
-
-
-
-
-
-
-
Increase (decrease) in cash and cash equivalents
$ 1,951
$ 2,909
$ 1,417
$ (782)
$ (3,163)
$ (290)
$ (407)
$ (1,236)
$ 493
$ 2,688
$ 23,931
$ 4,299